Y-27632 dihydrochloride: Selective ROCK1/2 Inhibitor for Cytoskeletal and Stem Cell Applications

Executive Summary: Y-27632 dihydrochloride potently inhibits ROCK1 (IC₅₀ ≈ 140 nM) and ROCK2 (K_i = 300 nM), showing >200-fold selectivity over related kinases. The compound disrupts Rho-mediated stress fiber formation, making it essential for cytoskeletal and cell motility studies (ApexBio). It enhances stem cell viability and survival, especially during dissociation and passaging (de Hoyos-Vega et al., 2023). Y-27632 reduces tumor invasion and metastasis in vivo and in vitro by modulating ROCK signaling. Its physicochemical properties enable versatile use in multiple solvents and model systems.

Biological Rationale

Rho-associated protein kinases (ROCK1 and ROCK2) are serine/threonine kinases involved in actin cytoskeleton regulation, cell shape, motility, and proliferation. Aberrant ROCK signaling is implicated in pathological processes like fibrosis, cancer metastasis, and stem cell apoptosis. Targeted inhibition of ROCK kinases allows precise dissection of Rho/ROCK pathway functions in experimental systems (Y-27632 Dihydrochloride: Selective ROCK Inhibitor for Stem Cell Applications). This article extends prior internal reviews by providing mechanistic and operational details for reproducible use of Y-27632 in cytoskeletal, stem cell, and invasion models.

Mechanism of Action of Y-27632 dihydrochloride

Y-27632 dihydrochloride is a small-molecule inhibitor targeting the catalytic domains of ROCK1 and ROCK2. It binds the ATP-binding pocket, competitively inhibiting kinase activity with an IC₅₀ of approximately 140 nM for ROCK1 and a K_i of 300 nM for ROCK2. This inhibition interrupts Rho-mediated phosphorylation events critical for actin-myosin contractility, leading to loss of stress fibers and focal adhesions in cultured cells (ApexBio). Y-27632 displays >200-fold selectivity over kinases such as PKC, MLCK, and PAK, reducing confounding off-target effects. ROCK inhibition modulates cell cycle progression, particularly the G1-S phase transition, and impairs cytokinesis (Y-27632 Dihydrochloride: Strategic ROCK Inhibition to Rewire Rho/ROCK Signaling), extending previous internal coverage by detailing its impact on cell division machinery.

Evidence & Benchmarks

• Y-27632 dihydrochloride inhibits ROCK1 with an IC₅₀ of 140 nM and ROCK2 with a K_i of 300 nM, demonstrating >200-fold selectivity over PKC, PKA, MLCK, and PAK (ApexBio).
• In vitro, Y-27632 reduces proliferation of prostatic smooth muscle cells in a concentration-dependent manner (ApexBio).
• Y-27632 enhances survival and viability of human intestinal organoid and stem cell cultures, particularly during mechanical dissociation (de Hoyos-Vega et al., 2023).
• In mouse models, Y-27632 suppresses tumor invasion and metastasis, correlating with decreased ROCK signaling and cytoskeletal rearrangements (Y-27632 Dihydrochloride: Advanced ROCK Inhibition for ISC Engineering).
• Y-27632 is soluble at ≥111.2 mg/mL in DMSO, ≥17.57 mg/mL in ethanol, and ≥52.9 mg/mL in water; solubility is increased by warming to 37°C or ultrasonic bath (ApexBio).

Applications, Limits & Misconceptions

Y-27632 dihydrochloride is widely used in basic and translational research. Applications include:

• Enhancing stem cell viability during isolation, passaging, and cryopreservation (de Hoyos-Vega et al., 2023).
• Dissecting cytoskeletal dynamics and Rho/ROCK pathway function in cell migration, adhesion, and morphology (Strategic ROCK Inhibition: Y-27632 Dihydrochloride as a Translational Tool), building on previous reviews by integrating new evidence from neurodevelopmental models.
• Modeling tumor invasion, metastasis, and cancer cell extravasation in both 2D and 3D systems.
• Studying cytokinesis and cell cycle regulation by selective ROCK inhibition.
• Engineering organoid and co-culture systems, including gut neuro-epithelial models (de Hoyos-Vega et al., 2023).

Common Pitfalls or Misconceptions

• Y-27632 does not inhibit non-ROCK kinases such as PKC, PKA, MLCK, and PAK at working concentrations; off-target effects are rare but possible at high doses.
• It is not suitable for long-term culture in solution; stock solutions should be stored below -20°C and used within several months.
• Y-27632 does not reverse established fibrosis or fully block all RhoA-mediated effects; it is specific to ROCK1/2-dependent pathways.
• Its use does not substitute for genetic knockout or RNAi approaches in definitive pathway studies.
• Solubility can be compromised if not warmed or sonicated; incomplete dissolution may affect experimental reproducibility.

Workflow Integration & Parameters

Y-27632 dihydrochloride is supplied as a solid and should be stored desiccated at 4°C or below. Prepare stock solutions in DMSO (≥111.2 mg/mL), ethanol (≥17.57 mg/mL), or water (≥52.9 mg/mL), warming to 37°C or using an ultrasonic bath if needed (ApexBio). For cell culture, typical working concentrations range from 1–10 μM, depending on cell type and endpoint. Avoid repeated freeze-thaw cycles of dissolved compound. In stem cell work, add Y-27632 during passaging and for 24–48 hours post-thaw or dissociation. For cancer invasion assays, pre-treat cells for 1–2 hours prior to migration or invasion setup. See Advanced ROCK Inhibition for ISC Engineering for detailed protocol contrast; this article adds solvent and storage stability data for reproducibility.

Conclusion & Outlook

Y-27632 dihydrochloride remains a cornerstone tool for selective ROCK inhibition in cytoskeletal, stem cell, and cancer research. Its high selectivity and robust performance across model systems facilitate reliable dissection of Rho/ROCK signaling mechanisms. Ongoing work is expanding Y-27632's applications to organoid, neurodevelopmental, and regenerative medicine models. For detailed product data and ordering information, see the Y-27632 dihydrochloride A3008 kit.